Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Digestive System Neuroendocrine Tumor G2”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Study completedNCT02893930
What this trial is testing

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Who this might be right for
Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma
National Cancer Institute (NCI) 13
Early research (Phase 1)Looking for participantsNCT07150546
What this trial is testing

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Who this might be right for
Digestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more
Emory University 15
Not applicableActive Not RecruitingNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Large-scale testing (Phase 3)Active Not RecruitingNCT03375320
What this trial is testing

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Who this might be right for
Functioning Pancreatic Neuroendocrine TumorIntermediate Grade Lung Neuroendocrine NeoplasmLocally Advanced Digestive System Neuroendocrine Neoplasm+25 more
National Cancer Institute (NCI) 298
Testing effectiveness (Phase 2)Study completedNCT01229943
What this trial is testing

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more
National Cancer Institute (NCI) 150
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Testing effectiveness (Phase 2)Looking for participantsNCT05773274
What this trial is testing

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Who this might be right for
Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)
Post-approval studies (Phase 4)Looking for participantsNCT06016855
What this trial is testing

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more
Vanderbilt-Ingram Cancer Center 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT01841736
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Who this might be right for
Foregut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1+5 more
National Cancer Institute (NCI) 171
100